- Sector
- Pharma & life sciences
- What's new
- ITC on free samples & expired stock
- Plus
- Inverted-duty refund on services & capital goods
- Effective
- From the next financial year
The short version
- Pharma companies will be able to claim GST input tax credit (ITC) on physician free samples and on goods destroyed or written off on expiry (where destruction is required by law) — from the next financial year.
- Inverted-duty refunds will now include input services and capital goods, easing a big pain point for a sector mostly at the 5% GST rate after GST 2.0.
- Together, experts call it a "double-dose booster" — unlocking blocked credit, improving liquidity and cash flow across manufacturers and exporters.
- The changes flow from the 57th GST Council and take effect through GST law and rule amendments from the next fiscal year.
For years, pharma companies have swallowed a quiet tax cost built into their own business model: GST credit lost on the physician samples they must distribute, and on the expired medicines the law itself requires them to destroy. The 57th GST Council has moved to end that — and, alongside, to fix the inverted-duty refund problem that a 5%-rated industry feels acutely. For pharma and life sciences, it's a meaningful working-capital win.
What's changing for pharma
| Change | What it means for pharma |
|---|---|
| ITC on free samples | Credit on inputs used for physician/trade samples — previously blocked — becomes available. |
| ITC on expired / destroyed goods | Credit need not be reversed on stock written off or destroyed on expiry of shelf life, where the law requires destruction. |
| Inverted-duty refund widened | Accumulated ITC on input services and capital goods becomes refundable under the inverted duty structure — not just goods. |
Why free samples and expiry matter so much here
Few industries manage sampling and expiry at pharma's scale. Physician samples are a routine, regulated part of how formulations, vaccines, biologics, diagnostics and consumer-healthcare products reach the market. And expiry-driven disposal isn't optional — regulation requires companies to destroy time-barred stock. Under the old rules, GST credit on both was effectively lost, taxing the company for doing exactly what its business and the law demand.
The end of a "punishing" tax hit
As one tax leader put it, unlocking ITC when medicines are destroyed after shelf-life expiry ends a punishing tax hit on inventory that the law itself requires companies to discard. That single change removes a cost that had nothing to do with profit or evasion — just the realities of pharma inventory.
The inverted-duty fix: the second dose
Post GST 2.0, much of pharma sits at a 5% output rate, while many inputs, input services and capital goods are taxed higher. That's a classic inverted duty structure — and credit piles up unused. By bringing input services and capital goods into the refund computation, the reform lets pharma manufacturers recover tax on professional services and on plant and equipment, instead of leaving it stuck in the credit ledger.
How the refund expansion phases in
In line with the 57th Council's framework, refund of accumulated ITC on input services applies to credit availed on or after 1 November 2026, and on capital goods (spread over 60 months) for credit availed on or after 1 April 2027. The changes don't cover past accumulated credit — which can still be used to pay tax.
Who benefits
- Formulation manufacturers managing large sampling and expiry cycles.
- Vaccine, biologics and diagnostics makers with significant manufacturing investment (capital goods).
- Consumer-healthcare companies with heavy product sampling.
- Exporters in the sector, who gain from faster, wider refunds freeing up working capital.
What pharma finance teams should do now
- Quantify the blocked credit you've been writing off on samples and expired-stock destruction — that's the cost about to be recovered.
- Map your inverted-duty position on input services and capital goods, and plan capex around the 1 Nov 2026 / 1 Apr 2027 effective dates.
- Tighten documentation — destruction records (as required by law), sample issue registers, and clean invoice data — so the credit and refunds stand up to scrutiny.
- Don't change treatment ahead of the law. Claim the new credits only once the amendments are notified and effective from the next fiscal year.
Timing note
These benefits take effect through GST law and rule amendments from the next financial year (with the inverted-duty refund dates noted above). Until the amendments are notified, the existing blocked-credit rules continue — so build the position now, but apply it only when it's live.
In pharma or life sciences?
efiletax helps pharma manufacturers and exporters map blocked ITC, structure inverted-duty refund claims, and keep destruction and sampling records audit-ready — so these reforms turn into real cash flow.
Talk to our GST teamDisclaimer: This article summarises GST ITC and refund reforms for the pharmaceutical sector recommended by the 57th GST Council (October 2026), based on official announcements and expert commentary, and is current as at the date of publication. The changes take effect through GST law, rule and notification amendments from the next financial year; specifics and effective dates may be refined. This is not legal or tax advice — please verify against the official documents and consult a qualified professional. Talk to efiletax if you need help.